Stockpolly
Search
VERU · NASDAQ · Biotechnology

Veru (VERU)

Develops oral candidates for obesity-related body composition and atherosclerotic inflammation.

$2.75
Pre-market+0.01 (+0.38%)
At close$2.74(+1.86%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Sep 2023Q1 FY24Dec 2023Q2 FY24Mar 2024Q3 FY24Jun 2024Q4 FY24Sep 2024Q1 FY25Dec 2024Q2 FY25Mar 2025Q3 FY25Jun 2025Q4 FY25Sep 2025Q1 FY26Dec 2025Q2 FY26Mar 2026Q3 FY26Jun 2026
Revenue404470000000
Cost of revenue203340000000
Gross profit201130000000
1081112111088−1578
Research & development823536433134
778885555443
Selling & marketing00000000−9000
General & administrative0000055014443
Other expenses−50000−1−10−9000
Operating income−8−8−10−11−8−10−8−81−5−7−8
110008000041
Interest expense000000000000
Other non-operating income270000110900−1
Income before tax−8−8−10−11−8−2−8−71−5−3−7
Income tax expense100000000000
Net income from continuing operations−8−8−10−11−9−2−8−71−5−3−7
Discontinued operations0−1000−7000000
Net income−8−8−10−11−9−9−8−71−5−3−7
EPS, basic−$0.90−$0.08−$0.07−$0.75−$0.58−$0.60−$0.54−$0.50$0.09−$0.26−$0.13−$0.30
EPS, diluted−$0.90−$0.08−$0.07−$0.75−$0.58−$0.60−$0.54−$0.50$0.09−$0.26−$0.13−$0.30
Weighted average shares, basic9101146151515151515202223
Weighted average shares, diluted9101146151515151515202223
EBITDA−36−8−10−11−8−11−9−8−7−5−7−7
Depreciation & amortization000000000000
EBIT−36−8−10−11−8−11−9−8−7−5−7−7